Unveiling the potency of FDA-approved oxidopamine HBr for cervical cancer regulation and replication proteins-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Unveiling the potency of FDA-approved oxidopamine HBr for cervical cancer regulation and replication proteins

Published:2024-08-09 Issue:9 Volume:41 Page:
ISSN:1559-131X
Container-title:Medical Oncology
language:en
Short-container-title:Med Oncol

Author:

Helmi Nawal,Hamadi Abdullah,Al-Amer Osama M.,Madkhali Hassan A.,Oyouni Atif Abdulwahab A.,Alqosaibi Amany I.,Almulhim Jawaher,Alghamdi Rashed Mohammed,Hakeem Israa J.,Rafeeq Misbahuddin M.^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s12032-024-02462-x.pdf

Reference41 articles.

1. Ahmad S et al., In-silico analysis reveals Quinic acid as a multitargeted inhibitor against cervical cancer. J Biomolecular Struct Dyn., 2022: p. 1–17.

2. Cohen PA, et al. Cervical cancer. Lancet. 2019;393(10167):169–82.

3. Siegel RL, Giaquinto AN, Jemal A, Cancer statistics, 2024. CA: Cancer J Clin. 2024. 74(1):12–49.

4. Plante M, et al. Simple versus radical hysterectomy in women with low-risk cervical cancer. N Engl J Med. 2024;390(9):819–29.

5. D’Arcy S, et al. Defining the molecular basis of BubR1 kinetochore interactions and APC/C-CDC20 inhibition. J Biol Chem. 2010;285(19):14764–76.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP